Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Infliximab for induction and maintenance therapy for ulcerative colitis.
Patients with moderate-to-severe active ulcerative colitis treated with infliximab at weeks 0, 2, and 6 and every eight weeks thereafter were more likely to have a clinical response at weeks 8, 30, and 54 than were those receiving placebo.
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Patients with moderate-to-severe Crohn's disease who were treated with infliximab plus azathioprine or inflIXimab monotherapy were more likely to have a corticosteroid-free clinical remission than those receiving azATHioprine monotherapy.
Infliximab maintenance therapy for fistulizing Crohn's disease.
Patients with fistulizing Crohn's disease who have a response to induction therapy with inflIXimab have an increased likelihood of a sustained response over a 54-week period if infliximab treatment is continued every 8 weeks.
Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.
- D. Rachmilewitz
- 14 January 1989
Mesalazine coated with Eudragit L is a safe, logical alternative to sulphasalazine in patients with active mild to moderate ulcerative colitis and remission rates were 74% and 81% in the two treatment groups respectively.
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease.
The scheduled infliximab groups, particularly the 10 mg/kg group, had better CDAI and Inflammatory Bowel Disease Questionnaire (IBDQ) responses than those in the episodic group.
Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis.
The protective effects of Probiotics are mediated by their own DNA rather than by their metabolites or ability to colonize the colon, and live microorganisms are not required to attenuate experimental colitis because nonviable probiotics are equally effective.
A Simple Classification of Crohn's Disease: Report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998
The aim of this international Working Party was to develop a simple classification of Crohn's disease based on objective variables, and the allocation of patients to these 24 subgroups proved feasible and resulted in specific disease clusters.
Toll-like receptor 9-induced type I IFN protects mice from experimental colitis.
- K. Katakura, Jongdae Lee, D. Rachmilewitz, Gloria C. Li, L. Eckmann, E. Raz
- BiologyJournal of Clinical Investigation
- 1 March 2005
Results indicate that TLR9-triggered type I IFN has antiinflammatory functions in colitis and suggest that strategies to modulate innate immunity may be of therapeutic value for the treatment of intestinal inflammatory conditions.
Enhanced colonic nitric oxide generation and nitric oxide synthase activity in ulcerative colitis and Crohn's disease.
- D. Rachmilewitz, J. Stamler, D. Bachwich, F. Karmeli, Z. Ackerman, D. Podolsky
- Medicine, BiologyGut
- 1 May 1995
The decrease in NOx generation by cultured colonic mucosa induced by methylprednisolone suggests that NO synthase activity is induced during the culture and the steroid effect may contribute to its therapeutic effect.